Baseline exhaled gas measurements and sampling
Throughout the experiment, a physician closely observed the subject and monitored his electrocardiogram and pulseoximetry to determine arterial carboxy-and oxy-hemoglobin fractions (FCOHb and FO 2 Hb), and blood pressure. The experiment was conducted in an operating room equipped with a forced ventilation system. During the experiment, the subject inhaled synthesized air (21% oxygen gas and 79% nitrogen gas), except for limited interruptions.
At the beginning of the experiment, the subject held his breath for 20 seconds and then exhaled into a 1.3-L gas-sampling bag (pylori exhaled gas sampling bag, Fukuda Denshi Co., Ltd., Tokyo, Japan). The procedure was repeated every 10 minutes, until 25 bags of exhaled gas were collected as baseline gas samples. The subject was then asked to breathe freely for 5 minutes using a device consisting of a respiratory circuit, a ventilator (E100, Newport Medical Instruments Inc., Costa Mesa, CA, USA), a mask, a flow sensor (TF-900P, Nihon Kohden Corp., Tokyo, Japan), an electrochemical sensor (Carbolizer mBA-1000, Taiyo Co., Ltd., Osaka, Japan), and a gas circuit with two one-way valves (Figure 1) . The E100 generates and regulates a constant 6 L/min flow of synthesized air. The Carbolizer electrochemical sensor is capable of determining the CO concentration in the outflow gas every second, at a resolution of 0.1 ppm (Sawano et al., 2006) . We processed simultaneous outputs from the Carbolizer and the TF-900P flow sensor to estimate the minute volume of CO (MVCO) and CO 2 (MVCO 2 ) in exhaled gas, each minute. The device is also capable of determining the end-tidal breath CO (ETCO) concentration with each breath.
Infusion of
13 CO-hemoglobin One week prior to initiation of the experiment, we estimated the circulating blood volume of the subject using the CO-hemoglobin dilution technique (Sawano et al., 2006) . We drew 0.45 L (approximately 9% of the estimated circulating blood volume) of venous blood from the subject, sealed it in a sterilized plastic bag with 100 units of heparin and 0.4 L of 100% 13 CO gas (Cambridge Isotope Laboratories, Inc., Andover, MA, USA), and then incubated the bag at 37°C for 30 minutes with gentle shaking to obtain 13 CO-saturated autologous blood. The FCOHb of the blood was determined using a CO-hemoximeter integrated into a blood gas analyzer (ABL-720, Radiometer Copenhagen Co., Ltd., Copenhagen, Denmark), and the 13 CO-saturated blood was infused back into the subject within 60 minutes.
During the infusion, venous blood was sampled every 5 minutes to determine the FCOHb using the ABL-720. The infusion was terminated when the FCOHb reached 9%.
Analysis of CO and
13 CO 2 production Following infusion, exhaled gas was collected in a 1.3-L bag, and the MVCO was measured every hour for the first 12 hours and every 4 hours thereafter, as was also done for baseline exhaled gas samples and MVCO measurement. Production of 13 CO 2 was monitored by measuring increases in the 13 CO 2 / 12 CO 2 ratio in exhaled gas samples using an infrared spectral analyzer (POCone, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan CO 2 ) at a resolution of a part per thousand. A single measurement required 120 mL of sample gas, and the measurement was repeated 10 times for each sample.
Venous blood was sampled every 4 hours to measure FCOHb, and the ETCO was estimated simultaneously using the device described in Figure 1 . The experiment was terminated 36 hours after infusion, when the Δ 13 CO 2 / 12 CO 2 , FCOHb, MVCO, and ETCO values had returned to baseline levels.
Quantitative analysis
The infused volume of CO ( 13 CO) was calculated from the FCOHb, solubility of CO, and volume of CO-saturated blood infused. We also calculated the total volumes of CO and CO 2 exhaled in the 37-hour period from the beginning of the infusion step until the end of the experiment by adding the measured MVCO and MVCO 2 values. The volume of endogenous CO exhaled during the experimental period was estimated from the baseline MVCO and then subtracted from the total to obtain the volume of exogenous CO derived from the infusion that was exhaled during the experimental period. From these values, the volume and percentage of the infused CO that was then either exhaled or retained in the body were estimated. The volume and percentage of CO 2 increased significantly (P < 0.05, vs. 0 hour) from 3 hours to 28 hours after the initiation of 13 CO-hemoglobin infusion, with a peak at 8 hours.
Time-course changes of MVCO and minute volume of 13 CO 2 (MV 13 CO 2 ) exhalations Changes in the MVCO and MV 13 CO 2 exhalations from the initiation of infusion until the end of the experiment are shown in Figure 4 .
The fate of CO in the body
The quantitative summary of the production and the fate of CO in the body, beginning at the time of CO infusion, until the end of the experiment, is shown in 
Statistical method
We applied Student's t-test and 5% significance level to assess the significance of increase in 13 CO 2 production. Figure 2 shows the changes in ETCO and FCOHb during Note: *1: The sum of the CO bound to hemoglobin and dissolved in the plasma. *2: The volume of CO exhaled, which was derived from either endogenous production or infusion (exogenous). *3: The volume and the percentage of infused CO ( 13 CO) that was either exhaled over the course of the experiment or retained in the body. *4: The volume of 13 CO 2 derived from oxidation of the infused 13 CO that was then exhaled during the experiment. Another study reported a significant increase in Δ 13 CO 2 / 12 CO 2 between 4 and 31 hours, with a peak at 9 hours after 13 CO inhalation, which exposed the airway epithelium to 50 ppm of 13 CO for 4 hours (Sawano and Shimouchi, 2010) . Thus, if the oxidation of CO occurs primarily in the airway epithelium, the increase and peak in 13 CO 2 production following 13 CO inhalation should have appeared 4 hours earlier compared with 13 CO-hemoglobin infusion. However, the time course of 13 CO 2 production following inhalation and infusion were almost identical in this study and the past, Sawano and Shimouchi (2010) suggesting that CO oxidation does not occur in the airway epithelium.
reSultS

Time-course changes of end tidal CO and CO-hemoglobin fraction
In the present study, quantitative analyses revealed that approximately 20% of the infused hemoglobin-bound CO was not exhaled between the initiation of infusion and termination of the experiment and was instead retained in the body. The ETCO, blood FCOHb, MVCO, MV 13 CO 2 and Δ 13 CO 2 / 12 CO 2 all returned to baseline levels at the end of the experimental period (Figures 2-4) . Therefore, we conclude that the percentage of the infused CO that was retained in the body had been redistributed from the blood into the tissue cells. Taken together, these results demonstrate that a portion of hemoglobin-bound CO moves from the blood to the tissues, where it is then oxidized. The elucidation of this pathway for the redistribution of CO from the circulating blood to the tissues strongly suggests that the role of endogenous CO is not limited to intracellular signal transmission but may extend to systemic or inter-organ signal transmission.
Previous studies estimated that 80% of the total CO body store is bound to hemoglobin in the red blood cells as carboxyhemoglobin and that 20% is bound to intracellular heme proteins (Coburn, 1967 (Coburn, , 1970 . Another study suggested that these CO body stores are exchangeable and that CO moves from the blood to the tissues, where it binds to heme proteins (Coburn and Mayers, 1971) . It is interesting that the ratio of the redistribution of CO from the blood to the tissues revealed by our quantitative analysis in the present study corresponds well with determinations of the distribution of CO body stores identified in these studies. However, the present study included only one subject; thus, further investigations involving more subjects are needed to derive definite conclusions. Another limitation of our quantitative analysis is that we did not measure CO emission from the skin. However, another study reported that the MVCO emission from the skin is no greater than 0.25% of the exhalation level (Nose and Shimouchi, 2008) , suggesting that this omission did not significantly affect the results of the present study.
In conclusion, our study demonstrated that a portion of hemoglobin-bound CO is redistributed from the blood to dIScuSSIon Previous studies have described the residual effects of CO after carboxyhemoglobin elimination in CO-intoxicated patients (Halperin et al., 1959) , the toxic effects of chronic exposure to low-concentration CO (Wang, 2004) , the poor correlation between blood carboxyhemoglobin levels and the physiologic effects of CO inhalation (Stewart, 1975) , and the protective effect against ischemia-reperfusion injury associated with CO inhalation in rats (Fujimoto et al., 2004) . These physiologic effects associated with CO inhalation cannot be explained by carboxyhemoglobin-induced hypoxia alone and instead suggest that CO is redistributed from the blood hemoglobin into tissue cells, where it activates or inhibits various heme protein enzymes (Coburn and Mayers, 1971; Piantadosi, 2002) . However, such a redistribution of CO under physiologic conditions has yet to be demonstrated (Wu and Wang, 2005) .
A previous study reported the production of 13 CO 2 in a human volunteer following the inhalation of 50 ppm of 13 CO gas (Sawano and Shimouchi, 2010) . In that study, human blood was circulated through a cardiopulmonary bypass circuit that simulates human blood circulation and gas exchange, with 50 ppm of 13 CO gas supplied to the oxygenator. However, no 13 CO 2 production was detected. These results demonstrated that under physiologic conditions CO is oxidized within the tissues rather than in the circulating blood (Sawano and Shimouchi, 2010) . Due to the possibility that the 13 CO 2 detected could have been derived from the oxidation of CO in the airway epithelium, however, the authors of that study were unable to definitively demonstrate the redistribution of CO from the blood to the tissues. the tissues, where it is then oxidized. However, the enzyme responsible for the oxidation of CO in the tissues of the human body remains to be identified. Several laboratory studies have demonstrated this enzymatic reaction using cytochrome C oxidase extracted from mitochondria of various animal organs (Tzagoloff and Wharton, 1965; Young and Caughey, 1986; Vijayasarathy et al., 1999) , but no study has traced the reaction in live human subjects. The enzyme is localized in mitochondria, which are eliminated from red blood cells during the course of their maturation (Zhang et al., 2009 ). Our study demonstrated that the oxidation of CO does not occur in the circulating blood and suggests that the enzyme responsible for the reaction is located in the tissues. However, further investigation is needed to test this hypothesis. A part of this paper was presented at the Breath Summit 2015, the scientific meeting of the International Association for Breath Research, 13-15 Sept. 2016, Vienna, Austria. Author contributions MS exclusively contributed to the study, read and approved the final version of this paper.
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